{
    "abstract": "Loss of airway microbial diversity is associated with non-typeable Haemophilus influenzae (NTHi) infection and increased risk of exacerbation in chronic obstructive pulmonary disease (COPD). We assessed the safety and immunogenicity of an investigational vaccine containing NTHi antigens, recombinant protein D (PD) and combined protein E and Pilin A (PE-PilA), and AS01 adjuvant in adults with moderate/severe COPD and prior exacerbations. In this phase 2, observer-blind, controlled trial (NCT02075541), 145 COPD patients aged 40\u201380 years randomly (1:1) received two doses of NTHi vaccine or placebo 60 days apart, on top of standard care. Reactogenicity in the 7-day post-vaccination period was higher following NTHi vaccine than placebo. Most solicited adverse events (AEs) were mild/moderate. At least one unsolicited AE was reported during the 30-day post-vaccination period by 54.8% of NTHi vaccine and 51.4% of placebo recipients. One serious AE (placebo group) was assessed by the investigator as vaccine-related. Anti-PD, anti-PE and anti-PilA geometric mean antibody concentrations increased up to 30 days after each NTHi vaccine dose, waned thereafter, but remained higher than baseline (non-overlapping confidence intervals) up to 13 months post-dose 2. The frequency of specific CD4+ T cells increased following two doses of NTHi vaccine and remained higher than baseline. Exploratory analysis showed a statistically non-significant lower yearly rate of moderate/severe exacerbations in the NTHi vaccine group than following placebo (1.49 versus 1.73) in the one-year period post-dose 2, with estimated vaccine efficacy of 13.3% (95% confidence interval \u221224.2 to 39.5; p = 0.44). The NTHi vaccine had an acceptable safety and reactogenicity profile and good immunogenicity in adults with COPD.",
    "author_highlights": [
        {
            "endOffset": 18155,
            "sentence": "An investigational NTHi vaccine was tested for the first time in adults with COPD.",
            "startOffset": 18073
        },
        {
            "endOffset": 18209,
            "sentence": "The vaccine had acceptable safety and reactogenicity.",
            "startOffset": 18156
        },
        {
            "endOffset": 18296,
            "sentence": "Vaccine-elicited antibody concentrations were higher than baseline 1 year post-dose 2.",
            "startOffset": 18210
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Alex J.",
                    "initial": "A.J.",
                    "last": "Mackay"
                },
                {
                    "first": "John R.",
                    "initial": "J.R.",
                    "last": "Hurst"
                }
            ],
            "doi": "10.1016/j.iac.2012.10.006",
            "firstpage": "95",
            "issn": "08898561",
            "lastpage": "115",
            "pmid": "23337067",
            "pub_year": 2013,
            "title": "COPD Exacerbations. Causes, Prevention, and Treatment",
            "volume": "33"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Robert P.",
                    "initial": "R.P.",
                    "last": "Dickson"
                },
                {
                    "first": "John R.",
                    "initial": "J.R.",
                    "last": "Erb-Downward"
                },
                {
                    "first": "Fernando J.",
                    "initial": "F.J.",
                    "last": "Martinez"
                },
                {
                    "first": "Gary B.",
                    "initial": "G.B.",
                    "last": "Huffnagle"
                }
            ],
            "doi": "10.1146/annurev-physiol-021115-105238",
            "firstpage": "481",
            "issn": "00664278",
            "lastpage": "504",
            "pmid": "26527186",
            "pub_year": 2016,
            "title": "The Microbiome and the Respiratory Tract",
            "volume": "78"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Zhang",
                    "initial": "Z.",
                    "last": "Wang"
                },
                {
                    "first": "Mona",
                    "initial": "M.",
                    "last": "Bafadhel"
                },
                {
                    "first": "Koirobi",
                    "initial": "K.",
                    "last": "Haldar"
                },
                {
                    "first": "Aaron",
                    "initial": "A.",
                    "last": "Spivak"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Mayhew"
                },
                {
                    "first": "Bruce E.",
                    "initial": "B.E.",
                    "last": "Miller"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Tal-Singer"
                },
                {
                    "first": "Sebastian L.",
                    "initial": "S.L.",
                    "last": "Johnston"
                },
                {
                    "first": "Mohammadali Yavari",
                    "initial": "M.Y.",
                    "last": "Ramsheh"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Barer"
                },
                {
                    "first": "Christopher E.",
                    "initial": "C.E.",
                    "last": "Brightling"
                },
                {
                    "first": "James R.",
                    "initial": "J.R.",
                    "last": "Brown"
                }
            ],
            "doi": "10.1183/13993003.01406-2015",
            "firstpage": "1082",
            "issn": "09031936",
            "lastpage": "1092",
            "pmid": "26917613",
            "pub_year": 2016,
            "title": "Lung microbiome dynamics in COPD exacerbations",
            "volume": "47"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Marc A.",
                    "initial": "M.A.",
                    "last": "Sze"
                },
                {
                    "first": "James C.",
                    "initial": "J.C.",
                    "last": "Hogg"
                },
                {
                    "first": "Don D.",
                    "initial": "D.D.",
                    "last": "Sin"
                }
            ],
            "doi": "10.2147/COPD.S38932",
            "firstpage": "229",
            "issn": "11769106",
            "lastpage": "238",
            "pmid": "24591822",
            "pub_year": 2014,
            "title": "Bacterial microbiome of lungs in COPD",
            "volume": "9"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Sethi"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Evans"
                },
                {
                    "first": "Brydon J.B.",
                    "initial": "B.J.B.",
                    "last": "Grant"
                },
                {
                    "first": "Timothy F.",
                    "initial": "T.F.",
                    "last": "Murphy"
                }
            ],
            "doi": "10.1056/NEJMoa012561",
            "firstpage": "465",
            "issn": "00284793",
            "lastpage": "471",
            "pmid": "12181400",
            "pub_year": 2002,
            "title": "New strains of bacteria and exacerbations of chronic obstructive pulmonary disease",
            "volume": "347"
        },
        "b0030": {
            "authors": [
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Mayhew"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Devos"
                },
                {
                    "first": "Christophe",
                    "initial": "C.",
                    "last": "Lambert"
                },
                {
                    "first": "James R.",
                    "initial": "J.R.",
                    "last": "Brown"
                },
                {
                    "first": "Stuart C.",
                    "initial": "S.C.",
                    "last": "Clarke"
                },
                {
                    "first": "Viktoriya L.",
                    "initial": "V.L.",
                    "last": "Kim"
                },
                {
                    "first": "Michal",
                    "initial": "M.",
                    "last": "Magid-Slav"
                },
                {
                    "first": "Bruce E.",
                    "initial": "B.E.",
                    "last": "Miller"
                },
                {
                    "first": "Kristoffer K.",
                    "initial": "K.K.",
                    "last": "Ostridge"
                },
                {
                    "first": "Ruchi",
                    "initial": "R.",
                    "last": "Patel"
                },
                {
                    "first": "Ganesh",
                    "initial": "G.",
                    "last": "Sathe"
                },
                {
                    "first": "Daniel F.",
                    "initial": "D.F.",
                    "last": "Simola"
                },
                {
                    "first": "Karl J.",
                    "initial": "K.J.",
                    "last": "Staples"
                },
                {
                    "first": "Ruby",
                    "initial": "R.",
                    "last": "Sung"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Tal-Singer"
                },
                {
                    "first": "Andrew C.",
                    "initial": "A.C.",
                    "last": "Tuck"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Van Horn"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Weynants"
                },
                {
                    "first": "Nicholas P.",
                    "initial": "N.P.",
                    "last": "Williams"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Devaster"
                },
                {
                    "first": "Tom M.A.",
                    "initial": "T.M.A.",
                    "last": "Wilkinson"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1136/thoraxjnl-2017-210408",
            "firstpage": "422",
            "issn": "14683296",
            "lastpage": "430",
            "pmid": "29386298",
            "pub_year": 2018,
            "title": "Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations",
            "volume": "73"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Davinder S.",
                    "initial": "D.S.",
                    "last": "Garcha"
                },
                {
                    "first": "Sarah J.",
                    "initial": "S.J.",
                    "last": "Thurston"
                },
                {
                    "first": "Anant R.C.",
                    "initial": "A.R.C.",
                    "last": "Patel"
                },
                {
                    "first": "Alexander J.",
                    "initial": "A.J.",
                    "last": "Mackay"
                },
                {
                    "first": "James J.P.",
                    "initial": "J.J.P.",
                    "last": "Goldring"
                },
                {
                    "first": "Gavin C.",
                    "initial": "G.C.",
                    "last": "Donaldson"
                },
                {
                    "first": "Timothy D.",
                    "initial": "T.D.",
                    "last": "McHugh"
                },
                {
                    "first": "Jadwiga A.",
                    "initial": "J.A.",
                    "last": "Wedzicha"
                }
            ],
            "doi": "10.1136/thoraxjnl-2012-201924",
            "firstpage": "1075",
            "issn": "00406376",
            "lastpage": "1080",
            "pmid": "22863758",
            "pub_year": 2012,
            "title": "Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD",
            "volume": "67"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Yvonne J.",
                    "initial": "Y.J.",
                    "last": "Huang"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Sethi"
                },
                {
                    "first": "Timothy",
                    "initial": "T.",
                    "last": "Murphy"
                },
                {
                    "first": "Snehal",
                    "initial": "S.",
                    "last": "Nariya"
                },
                {
                    "first": "Homer A.",
                    "initial": "H.A.",
                    "last": "Boushey"
                },
                {
                    "first": "Susan V.",
                    "initial": "S.V.",
                    "last": "Lynch"
                }
            ],
            "doi": "10.1128/JCM.00035-14",
            "firstpage": "2813",
            "issn": "00951137",
            "lastpage": "2823",
            "pmid": "24850358",
            "pub_year": 2014,
            "title": "Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease",
            "volume": "52"
        },
        "b0045": {
            "authors": [
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Millares"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Ferrari"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Gallego"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Garcia-Nu\u00f1ez"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "P\u00e9rez-Brocal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Espasa"
                },
                {
                    "first": "X.",
                    "initial": "X.",
                    "last": "Pomares"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Monton"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Moya"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Alons\u00f3"
                }
            ],
            "doi": "10.1007/s10096-013-2044-0",
            "firstpage": "1101",
            "issn": "09349723",
            "lastpage": "1111",
            "pmid": "24449346",
            "pub_year": 2014,
            "title": "Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa",
            "volume": "33"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Huaying",
                    "initial": "H.",
                    "last": "Wang"
                },
                {
                    "first": "Xiao",
                    "initial": "X.",
                    "last": "Gu"
                },
                {
                    "first": "Yuesong",
                    "initial": "Y.",
                    "last": "Weng"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Xu"
                },
                {
                    "first": "Zhongming",
                    "initial": "Z.",
                    "last": "Fu"
                },
                {
                    "first": "Weidong",
                    "initial": "W.",
                    "last": "Peng"
                },
                {
                    "first": "Wanjun",
                    "initial": "W.",
                    "last": "Yu"
                }
            ],
            "doi": "10.1186/s12890-015-0094-z",
            "issn": "14712466",
            "pmid": "26286268",
            "pub_year": 2015,
            "title": "Quantitative analysis of pathogens in the lower respiratory tract of patients with chronic obstructive pulmonary disease",
            "volume": "15"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Tom M.A.",
                    "initial": "T.M.A.",
                    "last": "Wilkinson"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Aris"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Bourne"
                },
                {
                    "first": "Stuart C.",
                    "initial": "S.C.",
                    "last": "Clarke"
                },
                {
                    "first": "Mathieu",
                    "initial": "M.",
                    "last": "Peeters"
                },
                {
                    "first": "Thierry G.",
                    "initial": "T.G.",
                    "last": "Pascal"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Schoonbroodt"
                },
                {
                    "first": "Andrew C.",
                    "initial": "A.C.",
                    "last": "Tuck"
                },
                {
                    "first": "Viktoriya",
                    "initial": "V.",
                    "last": "Kim"
                },
                {
                    "first": "Kristoffer",
                    "initial": "K.",
                    "last": "Ostridge"
                },
                {
                    "first": "Karl J.",
                    "initial": "K.J.",
                    "last": "Staples"
                },
                {
                    "first": "Nicholas",
                    "initial": "N.",
                    "last": "Williams"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Williams"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Wootton"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Devaster"
                }
            ],
            "doi": "10.1136/thoraxjnl-2016-209023",
            "issn": "00406376",
            "pmid": "28432209",
            "pub_year": 2017,
            "title": "A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD"
        },
        "b0060": null,
        "b0065": {
            "authors": [
                {
                    "first": "R. L.",
                    "initial": "R.L.",
                    "last": "Clancy"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Dunkley"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Sockler"
                },
                {
                    "first": "C. F.",
                    "initial": "C.F.",
                    "last": "Mcdonald"
                }
            ],
            "doi": "10.1111/imj.13072",
            "firstpage": "684",
            "issn": "14440903",
            "lastpage": "693",
            "pmid": "27009822",
            "pub_year": 2016,
            "title": "Multi-site placebo-controlled randomised clinical trial to assess protection following oral immunisation with inactivated non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease",
            "volume": "46"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Teo"
                },
                {
                    "first": "Hugh",
                    "initial": "H.",
                    "last": "House"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Lockhart"
                },
                {
                    "first": "Sai Navya",
                    "initial": "S.N.",
                    "last": "Purchuri"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Pushparajah"
                },
                {
                    "first": "Allan W.",
                    "initial": "A.W.",
                    "last": "Cripps"
                },
                {
                    "first": "Mieke L.",
                    "initial": "M.L.",
                    "last": "van Driel"
                }
            ],
            "doi": "10.1002/14651858.CD010010.pub2",
            "issn": "1469493X",
            "pmid": "25201571",
            "pub_year": 2014,
            "title": "Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease",
            "volume": "2014"
        },
        "b0075": {
            "authors": [
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Bakaletz"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Cripps"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Denoel"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Forsgren"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Kyd"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Lobet"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00288-7",
            "firstpage": "S108",
            "issn": "0264410X",
            "lastpage": "S115",
            "pmid": "11163473",
            "pub_year": 2000,
            "title": "Developing a nontypeable Haemophilus influenzae (NTHi) vaccine",
            "volume": "19"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Timothy F.",
                    "initial": "T.F.",
                    "last": "Murphy"
                }
            ],
            "doi": "10.1128/CVI.00089-15",
            "firstpage": "459",
            "issn": "15566811",
            "lastpage": "466",
            "pmid": "25787137",
            "pub_year": 2015,
            "title": "Vaccines for nontypeable Haemophilus influenzae: The future is now",
            "volume": "22"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Arne",
                    "initial": "A.",
                    "last": "Forsgren"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                },
                {
                    "first": "H\u00e5kan",
                    "initial": "H.",
                    "last": "Janson"
                }
            ],
            "doi": "10.1086/527396",
            "firstpage": "726",
            "issn": "10584838",
            "lastpage": "731",
            "pmid": "18230042",
            "pub_year": 2008,
            "title": "Protein D of Haemophilus influenzae: A protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines",
            "volume": "46"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1586/erv.09.113",
            "firstpage": "1479",
            "issn": "14760584",
            "lastpage": "1500",
            "pmid": "19863240",
            "pub_year": 2009,
            "title": "10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix\u2122",
            "volume": "8"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Birendra",
                    "initial": "B.",
                    "last": "Singh"
                },
                {
                    "first": "Tamim",
                    "initial": "T.",
                    "last": "Al-Jubair"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "M\u00f6rgelin"
                },
                {
                    "first": "Marjolein M.",
                    "initial": "M.M.",
                    "last": "Thunnissen"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                }
            ],
            "doi": "10.1128/IAI.01111-12",
            "firstpage": "801",
            "issn": "00199567",
            "lastpage": "814",
            "pmid": "23275089",
            "pub_year": 2013,
            "title": "The unique structure of haemophilus influenzae protein E reveals multiple binding sites for host factors",
            "volume": "81"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Teresia",
                    "initial": "T.",
                    "last": "Hallstr\u00f6m"
                },
                {
                    "first": "Anna M.",
                    "initial": "A.M.",
                    "last": "Blom"
                },
                {
                    "first": "Peter F.",
                    "initial": "P.F.",
                    "last": "Zipfel"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                }
            ],
            "doi": "10.4049/jimmunol.0803226",
            "firstpage": "2593",
            "issn": "00221767",
            "lastpage": "2601",
            "pmid": "19635912",
            "pub_year": 2009,
            "title": "Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance",
            "volume": "183"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Birendra",
                    "initial": "B.",
                    "last": "Singh"
                },
                {
                    "first": "Farshid",
                    "initial": "F.",
                    "last": "Jalalvand"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "M\u00f6rgelin"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Zipfel"
                },
                {
                    "first": "Anna M.",
                    "initial": "A.M.",
                    "last": "Blom"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                }
            ],
            "doi": "10.1111/j.1365-2958.2011.07678.x",
            "firstpage": "80",
            "issn": "0950382X",
            "lastpage": "98",
            "pmid": "21542857",
            "pub_year": 2011,
            "title": "Haemophilus influenzae protein E recognizes the C-terminal domain of vitronectin and modulates the membrane attack complex",
            "volume": "81"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Joseph A.",
                    "initial": "J.A.",
                    "last": "Jurcisek"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Bookwalter"
                },
                {
                    "first": "Beth D.",
                    "initial": "B.D.",
                    "last": "Baker"
                },
                {
                    "first": "Soledad",
                    "initial": "S.",
                    "last": "Fernandez"
                },
                {
                    "first": "Laura A.",
                    "initial": "L.A.",
                    "last": "Novotny"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Munson"
                },
                {
                    "first": "Lauren O.",
                    "initial": "L.O.",
                    "last": "Bakaletz"
                }
            ],
            "doi": "10.1111/j.1365-2958.2007.05864.x",
            "firstpage": "1288",
            "issn": "0950382X",
            "lastpage": "1299",
            "pmid": "17645732",
            "pub_year": 2007,
            "title": "The PilA protein of non-typeable Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract",
            "volume": "65"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Wouter",
                    "initial": "W.",
                    "last": "Haazen"
                },
                {
                    "first": "Sepehr",
                    "initial": "S.",
                    "last": "Shakib"
                },
                {
                    "first": "Magalie",
                    "initial": "M.",
                    "last": "Caubet"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Aris"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Devaster"
                },
                {
                    "first": "Mathieu",
                    "initial": "M.",
                    "last": "Peeters"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.04.051",
            "firstpage": "3156",
            "issn": "0264410X",
            "lastpage": "3163",
            "pmid": "27133877",
            "pub_year": 2016,
            "title": "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults",
            "volume": "34"
        },
        "b0120": {
            "authors": [
                {
                    "first": "N. R.",
                    "initial": "N.R.",
                    "last": "Anthonisen"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Manfreda"
                },
                {
                    "first": "C. P.W.",
                    "initial": "C.P.W.",
                    "last": "Warren"
                }
            ],
            "doi": "10.7326/0003-4819-106-2-196",
            "firstpage": "196",
            "issn": "00034819",
            "lastpage": "204",
            "pmid": "3492164",
            "pub_year": 1987,
            "title": "Antiobiotic therapy in exacerbations of chronic obstructive pulmonary disease",
            "volume": "106"
        },
        "b0125": null,
        "b0130": {
            "authors": [
                {
                    "first": "Fernanda",
                    "initial": "F.",
                    "last": "Tavares Da Silva"
                },
                {
                    "first": "Filip",
                    "initial": "F.",
                    "last": "De Keyser"
                },
                {
                    "first": "Paul Henri",
                    "initial": "P.H.",
                    "last": "Lambert"
                },
                {
                    "first": "William H.",
                    "initial": "W.H.",
                    "last": "Robinson"
                },
                {
                    "first": "Ren\u00e9",
                    "initial": "R.",
                    "last": "Westhovens"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Sindic"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.01.042",
            "firstpage": "1870",
            "issn": "0264410X",
            "lastpage": "1876",
            "pmid": "23391600",
            "pub_year": 2013,
            "title": "Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines",
            "volume": "31"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Robbert",
                    "initial": "R.",
                    "last": "Van Der Most"
                },
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Mamadou",
                    "initial": "M.",
                    "last": "Dram\u00e9"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Hanon"
                },
                {
                    "first": "Geert G.",
                    "initial": "G.G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                }
            ],
            "doi": "10.1007/s10875-010-9490-6",
            "firstpage": "443",
            "issn": "02719142",
            "lastpage": "454",
            "pmid": "21174144",
            "pub_year": 2011,
            "title": "H5N1 influenza vaccine formulated with AS03 A induces strong Cross-reactive and polyfunctional CD4 T-Cell responses",
            "volume": "31"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Devaster"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Hermand"
                },
                {
                    "first": "Pascale",
                    "initial": "P.",
                    "last": "Van Belle"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Vandepapeli\u00e8re"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Horsmans"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.10.052",
            "firstpage": "577",
            "issn": "0264410X",
            "lastpage": "584",
            "pmid": "24176494",
            "pub_year": 2015,
            "title": "Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials",
            "volume": "33"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Berglund"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Vink"
                },
                {
                    "first": "Fernanda Tavares",
                    "initial": "F.T.",
                    "last": "Da Silva"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Lestrate"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                }
            ],
            "doi": "10.1128/CVI.00430-13",
            "firstpage": "56",
            "issn": "15566811",
            "lastpage": "65",
            "pmid": "24173029",
            "pub_year": 2014,
            "title": "Safety, immunogenicity, and antibody persistence following an investigational streptococcus pneumoniae and haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults",
            "volume": "21"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Anna C.",
                    "initial": "A.C.",
                    "last": "Nilsson"
                },
                {
                    "first": "Magalie",
                    "initial": "M.",
                    "last": "Caubet"
                },
                {
                    "first": "Thierry G.",
                    "initial": "T.G.",
                    "last": "Pascal"
                },
                {
                    "first": "Pascale",
                    "initial": "P.",
                    "last": "Van Belle"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Pierre G.",
                    "initial": "P.G.",
                    "last": "Vandepapeli\u00e8re"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Peter E.",
                    "initial": "P.E.",
                    "last": "Vink"
                }
            ],
            "doi": "10.1128/CVI.00807-13",
            "firstpage": "651",
            "issn": "15566811",
            "lastpage": "660",
            "pmid": "24599529",
            "pub_year": 2014,
            "title": "Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02Vin elderly adults",
            "volume": "21"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Sunita",
                    "initial": "S.",
                    "last": "Awate"
                },
                {
                    "first": "Lorne A.",
                    "initial": "L.A.",
                    "last": "Babiuk"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Mutwiri"
                }
            ],
            "doi": "10.3389/fimmu.2013.00114",
            "issn": "16643224",
            "pub_year": 2013,
            "title": "Mechanisms of action of adjuvants",
            "volume": "4"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Arnaud M.",
                    "initial": "A.M.",
                    "last": "Didierlaurent"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Collignon"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Bourguignon"
                },
                {
                    "first": "Sandrine",
                    "initial": "S.",
                    "last": "Wouters"
                },
                {
                    "first": "Kaat",
                    "initial": "K.",
                    "last": "Fierens"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Fochesato"
                },
                {
                    "first": "Najoua",
                    "initial": "N.",
                    "last": "Dendouga"
                },
                {
                    "first": "Christelle",
                    "initial": "C.",
                    "last": "Langlet"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Malissen"
                },
                {
                    "first": "Bart N.",
                    "initial": "B.N.",
                    "last": "Lambrecht"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Morel"
                }
            ],
            "doi": "10.4049/jimmunol.1400948",
            "firstpage": "1920",
            "issn": "00221767",
            "lastpage": "1930",
            "pmid": "25024381",
            "pub_year": 2014,
            "title": "Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells",
            "volume": "193"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Kent E.",
                    "initial": "K.E.",
                    "last": "Kester"
                },
                {
                    "first": "James F.",
                    "initial": "J.F.",
                    "last": "Cummings"
                },
                {
                    "first": "Opokua",
                    "initial": "O.",
                    "last": "Ofori-Anyinam"
                },
                {
                    "first": "Christian F.",
                    "initial": "C.F.",
                    "last": "Ockenhouse"
                },
                {
                    "first": "Urszula",
                    "initial": "U.",
                    "last": "Krzych"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Schwenk"
                },
                {
                    "first": "Robin A.",
                    "initial": "R.A.",
                    "last": "Nielsen"
                },
                {
                    "first": "Zufan",
                    "initial": "Z.",
                    "last": "Debebe"
                },
                {
                    "first": "Evgeny",
                    "initial": "E.",
                    "last": "Pinelis"
                },
                {
                    "first": "Laure",
                    "initial": "L.",
                    "last": "Juompan"
                },
                {
                    "first": "Jack",
                    "initial": "J.",
                    "last": "Williams"
                },
                {
                    "first": "Megan",
                    "initial": "M.",
                    "last": "Dowler"
                },
                {
                    "first": "V. Ann",
                    "initial": "V.A.",
                    "last": "Stewart"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Wirtz"
                },
                {
                    "first": "Marie Claude",
                    "initial": "M.C.",
                    "last": "Dubois"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Lievens"
                },
                {
                    "first": "Joe",
                    "initial": "J.",
                    "last": "Cohen"
                },
                {
                    "first": "W. Ripley",
                    "initial": "W.R.",
                    "last": "Ballou"
                },
                {
                    "first": "D. Gray",
                    "initial": "D.G.",
                    "last": "Heppner"
                }
            ],
            "doi": "10.1086/600120",
            "firstpage": "337",
            "issn": "00221899",
            "lastpage": "346",
            "pmid": "19569965",
            "pub_year": 2009,
            "title": "Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection",
            "volume": "200"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Vandepapeli\u00e8re"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Horsmans"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Janssens"
                },
                {
                    "first": "Marguerite",
                    "initial": "M.",
                    "last": "Koutsoukos"
                },
                {
                    "first": "Pascale",
                    "initial": "P.",
                    "last": "Van Belle"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Hanon"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Wettendorff"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.12.038",
            "firstpage": "1375",
            "issn": "0264410X",
            "lastpage": "1386",
            "pmid": "18272264",
            "pub_year": 2008,
            "title": "Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers",
            "volume": "26"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Van Braeckel"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Bourguignon"
                },
                {
                    "first": "Marguerite",
                    "initial": "M.",
                    "last": "Koutsoukos"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Janssens"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Carletti"
                },
                {
                    "first": "Alix",
                    "initial": "A.",
                    "last": "Collard"
                },
                {
                    "first": "Marie Ange",
                    "initial": "M.A.",
                    "last": "Demoiti\u00e9"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Voss"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "McNally"
                }
            ],
            "doi": "10.1093/cid/ciq160",
            "firstpage": "522",
            "issn": "10584838",
            "lastpage": "531",
            "pmid": "21208909",
            "pub_year": 2011,
            "title": "An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers",
            "volume": "52"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Arnaud",
                    "initial": "A.",
                    "last": "Marchant"
                },
                {
                    "first": "Jack",
                    "initial": "J.",
                    "last": "Levy"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Horsmans"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Jilg"
                },
                {
                    "first": "Peter G.",
                    "initial": "P.G.",
                    "last": "Kremsner"
                },
                {
                    "first": "Edwige",
                    "initial": "E.",
                    "last": "Haelterman"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Cl\u00e9ment"
                },
                {
                    "first": "Julian J.",
                    "initial": "J.J.",
                    "last": "Gabor"
                },
                {
                    "first": "Meral",
                    "initial": "M.",
                    "last": "Esen"
                },
                {
                    "first": "Annick",
                    "initial": "A.",
                    "last": "Hens"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Carletti"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Fissette"
                },
                {
                    "first": "Fernanda",
                    "initial": "F.",
                    "last": "Tavares Da Silva"
                },
                {
                    "first": "Wivine",
                    "initial": "W.",
                    "last": "Burny"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Janssens"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Arnaud M.",
                    "initial": "A.M.",
                    "last": "Didierlaurent"
                },
                {
                    "first": "Robbert",
                    "initial": "R.",
                    "last": "Van Der Most"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Pascale",
                    "initial": "P.",
                    "last": "Van Belle"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                }
            ],
            "doi": "10.1016/j.clim.2016.05.007",
            "firstpage": "16",
            "issn": "15216616",
            "lastpage": "27",
            "pmid": "27236001",
            "pub_year": 2016,
            "title": "Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial",
            "volume": "169"
        }
    },
    "body_text": [
        {
            "endOffset": 32738,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Statistical analyses were performed using Statistical Analysis Systems (SAS) version 9.2.",
            "startOffset": 32649,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 24597,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Each participant was, in the opinion of the investigator, capable of complying with the requirements of the protocol, including regular sputum production.",
            "startOffset": 24443,
            "title": "Study design and patients"
        },
        {
            "endOffset": 27154,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol is available at https://www.gsk-studyregister.com (study identifier, 200157).",
            "startOffset": 27058,
            "title": "Study design and patients"
        },
        {
            "endOffset": 40734,
            "parents": [],
            "secId": "s0065",
            "sentence": "The most commonly reported solicited local AE was pain, with overall per subject incidences of 80.8% (95% CI: 69.9\u201389.1) in the NTHi vaccine group and 12.5% (95% CI: 5.9\u201322.4) in the placebo group, while the most common solicited general AE was fatigue, with overall per subject incidences of 50.7% (95% CI: 38.7\u201362.6) and 31.9% (95% CI: 21.4\u201344.0), respectively.",
            "startOffset": 40371,
            "title": "Discussion"
        },
        {
            "endOffset": 32180,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The frequency of specific CD4+ and CD8+ T cells was summarised for a subset of subjects using descriptive statistics.",
            "startOffset": 32063,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 36779,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Three grade 3 abnormal haematology or biochemistry results were reported in three participants (4.1%) in the NTHi vaccine group and eight were reported by six participants (8.3%) in the placebo group.",
            "startOffset": 36579,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 37926,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Frequencies overlapped between groups but tended to be higher in the NTHi group.",
            "startOffset": 37846,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 43107,
            "parents": [],
            "secId": "s0065",
            "sentence": "Also, the low number of subjects included in the CMI response analysis and high variability in the results limited the ability to interpret these data.",
            "startOffset": 42956,
            "title": "Discussion"
        },
        {
            "endOffset": 29454,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Blood samples for CMI response analysis were taken before vaccination, 30 days after the second vaccination and at Days 270 and 450 in a sub-cohort of patients (15 per group) selected randomly using a centralised randomisation system (SBIR).",
            "startOffset": 29213,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 34606,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "There were four reports of grade 3 solicited general events related to vaccination (two fatigue, two headache) after the first NTHi vaccine dose and six (three fatigue, two headache, one gastrointestinal symptoms) after the second dose, all of which resolved spontaneously and lasted no longer than 3 days, apart from one report of headache post-dose 2 that lasted 7 days.",
            "startOffset": 34234,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 28606,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Sera were stored at \u221220 \u00b0C until assayed.",
            "startOffset": 28565,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 31600,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The NTHi vaccine group and placebo group were considered significantly different if the 95% CI for the GMC ratio (adjusted for baseline concentration) between the two groups did not contain 1.",
            "startOffset": 31408,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 43400,
            "parents": [],
            "secId": "s0065",
            "sentence": "In conclusion, the data from this phase 2 study demonstrate that the investigational NTHi vaccine has an acceptable safety and reactogenicity profile, induces substantial humoral responses and elicits NTHi-specific CD4+ T cell responses in adults aged 40\u201380 years with moderate or severe COPD.",
            "startOffset": 43107,
            "title": "Discussion"
        },
        {
            "endOffset": 25799,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Patients were randomised (1:1) to receive, on top of standard care, two doses by intramuscular injection 60 days apart of the investigational NTHi vaccine or saline placebo using a centralised randomisation system (SBIR), with a minimisation procedure accounting for age category (40\u201359 or 60\u201380 years), number of moderate or severe exacerbations in the previous year (<2 or \u22652) and GOLD stage (2 or 3).",
            "startOffset": 25396,
            "title": "Study design and patients"
        },
        {
            "endOffset": 30968,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibody GMCs and their 95% CIs were determined.",
            "startOffset": 30920,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33775,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Pain and fatigue were the most frequently reported solicited local and general AEs, respectively, during the 7-day post-vaccination period (Fig. 3).",
            "startOffset": 33627,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 27753,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Grade 3 redness or swelling was defined as diameter > 100 mm and grade 3 fever as temperature > 39.5 \u00b0C.",
            "startOffset": 27649,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 28134,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 28133,
                    "startOffset": 28129
                }
            },
            "secId": "s0020",
            "sentence": "Abnormal laboratory findings that were judged by the investigator to be clinically significant were recorded as an AE or serious AE (SAE) and graded 1\u20134 [25].",
            "startOffset": 27976,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 29939,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Exacerbations, detected using daily electronic diary cards, were recorded as mild, moderate or severe (see supplementary methods).",
            "startOffset": 29809,
            "title": "Vaccine efficacy"
        },
        {
            "endOffset": 32455,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "To assess clinical efficacy, VE was estimated from the yearly rate of AECOPD calculated from one month post-dose 2 in the total vaccinated cohort, using a negative binomial model with treatment group, country, GOLD stage, history of exacerbations and age category as factors.",
            "startOffset": 32180,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38924,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For AECOPD of any severity, there were 130 reports by 73 patients in the NTHi group and 140 by 71 patients following placebo, with estimated VE of 10.5% (95% CI: \u221223.6, 35.1; p = 0.50).",
            "startOffset": 38739,
            "title": "Efficacy"
        },
        {
            "endOffset": 42109,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 42108,
                    "startOffset": 42098
                },
                "b0165": {
                    "endOffset": 42108,
                    "startOffset": 42098
                },
                "b0170": {
                    "endOffset": 42108,
                    "startOffset": 42098
                },
                "b0175": {
                    "endOffset": 42108,
                    "startOffset": 42098
                },
                "b0180": {
                    "endOffset": 42108,
                    "startOffset": 42098
                }
            },
            "secId": "s0065",
            "sentence": "There was no CD8+ T cell induction detected, as observed in other studies of AS01-adjuvanted vaccines in adults [23,33\u201336].",
            "startOffset": 41986,
            "title": "Discussion"
        },
        {
            "endOffset": 39069,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Seventeen patients (23.3%) in the NTHi group and 20 (28.2%) receiving placebo reported no exacerbations (any cause: infection-related or other).",
            "startOffset": 38925,
            "title": "Efficacy"
        },
        {
            "endOffset": 27648,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "AE intensity was graded on a 0\u20133 scale.",
            "startOffset": 27609,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 26687,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The primary objective was to assess safety and reactogenicity and the secondary objective was to describe the vaccine\u2019s humoral and cellular immunogenicity.",
            "startOffset": 26531,
            "title": "Study design and patients"
        },
        {
            "endOffset": 30919,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The immunogenicity analysis was performed on the according-to-protocol (ATP) cohort for immunogenicity, i.e. eligible patients who received the study vaccine correctly and complied with study procedures; patients who received immune-modifying treatment for > 14 days were eliminated.",
            "startOffset": 30636,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 27290,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.",
            "startOffset": 27155,
            "title": "Study design and patients"
        },
        {
            "endOffset": 28564,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Immunoglobulin G antibody geometric mean concentrations (GMCs) to each vaccine antigen were measured by enzyme-linked immunosorbent assay (ELISA), developed and optimised by GSK Biologicals, of blood samples taken before and 30 days after each vaccination, and at Days 270 and 450.",
            "startOffset": 28283,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 20648,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 20647,
                    "startOffset": 20644
                }
            },
            "secId": "s0005",
            "sentence": "Acute exacerbations contribute substantially to the morbidity and mortality of chronic obstructive pulmonary disease (COPD) [1].",
            "startOffset": 20520,
            "title": "Introduction"
        },
        {
            "endOffset": 35541,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Grade 3 vaccine-related unsolicited AEs were reported by two (2.8%) participants in the placebo group (nasopharyngitis and migraine, lasting 15 days and 1 day, respectively) and four participants (5.5%) in the NTHi vaccine group: fatigue (two participants; duration 2 and 4 days), headache (one participant; duration 7 days) and dizziness, cough, oropharyngeal pain and rhinorrhoea (one participant; oropharyngeal pain lasting 45 days, duration unknown for other AEs).",
            "startOffset": 35073,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 31407,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The model included country, age category, number of moderate or severe exacerbations in the previous year (<2 or \u22652), GOLD stage and baseline concentration (as covariate) as fixed effects.",
            "startOffset": 31219,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 21019,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 21018,
                    "startOffset": 21015
                }
            },
            "secId": "s0005",
            "sentence": "In the prospective, observational cohort study, Acute Exacerbation and Respiratory InfectionS in COPD (AERIS), loss of microbial diversity was associated with non-typeable Haemophilus influenzae (NTHi) infection and increased risk of exacerbation [6].",
            "startOffset": 20768,
            "title": "Introduction"
        },
        {
            "endOffset": 39700,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Time to first AECOPD tended to be longer in the NTHi group than in the placebo group (Fig. 6), although the difference between groups was not statistically significant (hazard ratio p = 0.23 for moderate/severe AECOPD, p = 0.44 for any AECOPD).",
            "startOffset": 39456,
            "title": "Efficacy"
        },
        {
            "endOffset": 38738,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the one-year period starting one month post-dose 2, the number of reports of moderate/severe AECOPD was lower in the NTHi group (107 in 73 patients) than following placebo (120 in 71 patients), albeit the difference between groups was not statistically significant, with estimated VE of 13.3% (\u221224.2, 39.5; p = 0.44) (Fig. 5).",
            "startOffset": 38409,
            "title": "Efficacy"
        },
        {
            "endOffset": 21155,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 21154,
                    "startOffset": 21148
                },
                "b0040": {
                    "endOffset": 21154,
                    "startOffset": 21148
                },
                "b0045": {
                    "endOffset": 21154,
                    "startOffset": 21148
                },
                "b0050": {
                    "endOffset": 21154,
                    "startOffset": 21148
                },
                "b0055": {
                    "endOffset": 21154,
                    "startOffset": 21148
                }
            },
            "secId": "s0005",
            "sentence": "AERIS and other studies also showed changes in the prevalence of airway bacteria at exacerbation compared with the stable state [7\u201311].",
            "startOffset": 21020,
            "title": "Introduction"
        },
        {
            "endOffset": 37723,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The frequency of NTHi antigen-specific CD4+ T cells expressing at least two markers among CD40L, IL-2, TNF-\u03b1, IFN-\u0263, IL-13 and IL-17 showed increases from baseline to 30 days after the second vaccine dose (supplementary Fig. S1).",
            "startOffset": 37494,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21520,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 21519,
                    "startOffset": 21512
                },
                "b0070": {
                    "endOffset": 21519,
                    "startOffset": 21512
                }
            },
            "secId": "s0005",
            "sentence": "An oral whole cell NTHi vaccine did not provide convincing protection against exacerbations of COPD or bronchitis [13,14].",
            "startOffset": 21398,
            "title": "Introduction"
        },
        {
            "endOffset": 33088,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Thirty-three patients were enrolled in Sweden (16 in vaccine group, 17 in control group) and 112 in the UK (57 and 55, respectively).",
            "startOffset": 32955,
            "title": "Study population"
        },
        {
            "endOffset": 34233,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Incidences of the solicited general symptoms in the NTHi vaccine group tended to be higher after the second dose, although 95% CIs overlapped (Fig. 3).",
            "startOffset": 34082,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 28680,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Standardised procedures and in-house-made serum were used for each assay.",
            "startOffset": 28607,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 35878,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "One SAE (infective exacerbation of COPD that lasted 37 days, reported by a 63-year-old patient at Day 200 after the second placebo dose) was considered by the investigator as causally related to vaccination.",
            "startOffset": 35671,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 27057,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All participants provided written informed consent before study entry.",
            "startOffset": 26987,
            "title": "Study design and patients"
        },
        {
            "endOffset": 30636,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Since the number of patients enrolled was limited, no formal statistical comparisons of reactogenicity were performed between groups.",
            "startOffset": 30503,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 32062,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Cellular immunity responses were expressed as the frequency of specific CD4+ or CD8+ T cells identified as expressing at least two markers upon in vitro stimulation with the relevant pool of peptides, after subtraction of the corresponding frequency of CD4+ or CD8+ T cells similarly \u201cstimulated\u201d with medium instead of the peptide pool (background frequency).",
            "startOffset": 31702,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37845,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "This was followed by a reduction in response up to the last time point, although responses remained higher than baseline.",
            "startOffset": 37724,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40237,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 40236,
                    "startOffset": 40232
                }
            },
            "secId": "s0065",
            "sentence": "The NTHi vaccine had an acceptable safety and reactogenicity profile in this group, which was consistent with findings from phase 1 studies of the investigational vaccine in healthy adults aged 18\u201340 years and current or former smokers aged 50\u201370 years without COPD [23].",
            "startOffset": 39966,
            "title": "Discussion"
        },
        {
            "endOffset": 32601,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A complementary post-hoc analysis was performed to evaluate time to first exacerbation event (any or moderate/severe) from one month post-dose 2.",
            "startOffset": 32456,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 34880,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In the placebo group, there were five reports of grade 3 vaccine-related general events (one fatigue, one gastrointestinal symptoms, two headache, one fever) after the first dose and three after the second dose (two fatigue, one headache) that lasted no longer than 2 days.",
            "startOffset": 34607,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 41236,
            "parents": [],
            "secId": "s0065",
            "sentence": "Overall, however, the reported solicited AEs were transient and mild to moderate in intensity.",
            "startOffset": 41142,
            "title": "Discussion"
        },
        {
            "endOffset": 22820,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 22690,
                    "startOffset": 22686
                }
            },
            "secId": "s0005",
            "sentence": "In that phase 1 study, and another conducted in healthy 18\u201340 year-olds [23], the NTHi vaccine formulations had an acceptable safety and reactogenicity profile and induced antigen-specific immune responses.",
            "startOffset": 22614,
            "title": "Introduction"
        },
        {
            "endOffset": 26530,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Patients were followed for approximately 15 months after the first vaccination.",
            "startOffset": 26451,
            "title": "Study design and patients"
        },
        {
            "endOffset": 28816,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The cut-off of the assays was 153 ELISA units (EU)/mL, 8 EU/mL and 7 EU/mL for anti-PD, anti-PE and anti-PilA antibodies, respectively.",
            "startOffset": 28681,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 24258,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A pack-year is defined as 20 cigarettes smoked every day for one year and the number of pack-years was calculated as: (average number of cigarettes smoked per day times number of years smoked) divided by 20.",
            "startOffset": 24051,
            "title": "Study design and patients"
        },
        {
            "endOffset": 33370,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Twenty-seven participants in each group were excluded from the ATP cohort for immunogenicity because of protocol deviations (Fig. 2).",
            "startOffset": 33237,
            "title": "Study population"
        },
        {
            "endOffset": 40961,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 40960,
                    "startOffset": 40950
                },
                "b0140": {
                    "endOffset": 40960,
                    "startOffset": 40950
                },
                "b0145": {
                    "endOffset": 40960,
                    "startOffset": 40950
                },
                "b0150": {
                    "endOffset": 40960,
                    "startOffset": 40950
                }
            },
            "secId": "s0065",
            "sentence": "Higher frequencies of solicited AEs in adjuvanted vaccine groups versus groups who received non-adjuvanted vaccine formulations or placebo were reported in previous studies, including the phase 1 NTHi vaccine study [23,28\u201330].",
            "startOffset": 40735,
            "title": "Discussion"
        },
        {
            "endOffset": 23035,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we report the results of a phase 2 placebo-controlled study in which the safety and reactogenicity of the investigational NTHi vaccine was evaluated, for the first time, in adults with moderate or severe COPD.",
            "startOffset": 22820,
            "title": "Introduction"
        },
        {
            "endOffset": 28245,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 28190,
                    "startOffset": 28186
                }
            },
            "secId": "s0020",
            "sentence": "Data on potential immune-mediated diseases (pIMDs) [26] and SAEs were collected for the duration of the study.",
            "startOffset": 28135,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 29212,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 29211,
                    "startOffset": 29207
                }
            },
            "secId": "s0025",
            "sentence": "NTHi-specific cell-mediated immune (CMI) responses (antigen-specific CD4+ and CD8+ T cells) were measured by flow cytometry using intracellular cytokine staining (ICS) on peripheral blood mononuclear cells, following an adaptation of previously described methods in which the T cells are re-stimulated by incubation with antigen in the presence of costimulatory antibodies to CD28 and CD49d [27].",
            "startOffset": 28816,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 32954,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Of 268 COPD patients who were screened, 145 met the inclusion criteria; 73 were enrolled and vaccinated in the NTHi vaccine group and 72 were enrolled in the placebo control group (Fig. 2).",
            "startOffset": 32765,
            "title": "Study population"
        },
        {
            "endOffset": 26232,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Due to differences in the appearance of the study vaccine and placebo formulation, the study was conducted in an observer-blind manner, i.e. vaccine/placebo recipients and those responsible for the evaluation of any study endpoint were blinded to the administered formulation and formulations were prepared and administered by authorised clinical personnel who did not participate in any of the study clinical evaluations or assays.",
            "startOffset": 25800,
            "title": "Study design and patients"
        },
        {
            "endOffset": 23765,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 23764,
                    "startOffset": 23760
                }
            },
            "secId": "s0015",
            "sentence": "Patients, enrolled between 6 August 2014 and 30 October 2015, were aged 40\u201380 years and had a confirmed diagnosis of COPD, with stage 2/3 (moderate to severe) airflow limitation, according to GOLD staging [12].",
            "startOffset": 23555,
            "title": "Study design and patients"
        },
        {
            "endOffset": 26785,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.",
            "startOffset": 26687,
            "title": "Study design and patients"
        },
        {
            "endOffset": 22613,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 22612,
                    "startOffset": 22608
                }
            },
            "secId": "s0005",
            "sentence": "Investigational NTHi vaccine formulations that included the Adjuvant System AS01E produced higher humoral and cellular immune responses in current or former smokers aged 50\u201370 years than those that included alum or non-adjuvanted formulations [23].",
            "startOffset": 22365,
            "title": "Introduction"
        },
        {
            "endOffset": 38306,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "There were no detectable specific CD8+ T cell responses (data not shown).",
            "startOffset": 38233,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 23554,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This randomised, observer-blind, placebo-controlled study was conducted in four centres in Sweden and 11 in the UK between 8 July 2014 and 19 April 2017 (ClinicalTrials.gov identifier: NCT02075541).",
            "startOffset": 23356,
            "title": "Study design and patients"
        },
        {
            "endOffset": 33236,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Sixty-nine participants in the NTHi vaccine group and 64 in the placebo group completed the study; reasons for discontinuation are shown in Fig. 2.",
            "startOffset": 33089,
            "title": "Study population"
        },
        {
            "endOffset": 30383,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The safety analysis was performed on the total vaccinated cohort, which included all vaccinated participants.",
            "startOffset": 30274,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33454,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Mean age in both groups was 67 years and around half of patients were men (Table 1).",
            "startOffset": 33370,
            "title": "Study population"
        },
        {
            "endOffset": 24050,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Current smokers were defined as people who were smoking or had stopped smoking less than six months before entry into the study and former smokers as people who had stopped smoking for at least six months.",
            "startOffset": 23845,
            "title": "Study design and patients"
        },
        {
            "endOffset": 25127,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "An AECOPD was defined as worsening of at least two major symptoms (dyspnoea, sputum volume and sputum purulence) or worsening of at least one major symptom and one minor symptom (sore throat, colds [nasal discharge and/or nasal congestion], fever [oral temperature \u2265 37.5 \u00b0C] without other cause, increased cough and increased wheeze) for at least two consecutive days.",
            "startOffset": 24758,
            "title": "Study design and patients"
        },
        {
            "endOffset": 30132,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Thus, sample size was based on estimates of the percentage of subjects in each group with AEs following vaccination.",
            "startOffset": 30016,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30273,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "With approximately 70 eligible COPD patients enrolled in each study group, the chance of detecting an AE with true incidence of 5% was >97%.",
            "startOffset": 30133,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30502,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The incidence of AEs per study group was calculated with exact 95% confidence intervals (CIs) after each vaccine dose.",
            "startOffset": 30384,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 35072,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "During the 30-day post-vaccination period, at least one unsolicited AE was reported by 54.8% of participants in the NTHi vaccine group and 51.4% of participants in the placebo group (Table 2).",
            "startOffset": 34880,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 35670,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Fifteen participants in the NTHi vaccine group and 17 in the placebo group reported a total of 62 SAEs (28 and 34, respectively).",
            "startOffset": 35541,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 30015,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The study\u2019s primary objective was to evaluate safety.",
            "startOffset": 29962,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31702,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "No adjustment for multiplicity was performed and the clinical relevance of any difference is unknown.",
            "startOffset": 31601,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 39250,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The observed yearly rate of moderate/severe AECOPD was 1.49 and 1.73 in the NTHi group and placebo group, respectively, and 1.80 and 2.02, respectively, for AECOPD of any severity.",
            "startOffset": 39070,
            "title": "Efficacy"
        },
        {
            "endOffset": 31218,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The between groups GMC ratio at one month post-dose 2 and its 95% CI for each vaccine antigen was computed with an analysis of covariance model that considers heterogeneity of variances (via Proc Mixed) on the log10 transformation of concentrations.",
            "startOffset": 30969,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41558,
            "parents": [],
            "secId": "s0065",
            "sentence": "The NTHi investigational vaccine induced substantial humoral immune responses and elicited specific CD4+ T cell responses in patients with COPD.",
            "startOffset": 41414,
            "title": "Discussion"
        },
        {
            "endOffset": 36164,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "There were three deaths; one in the NTHi group (68-year-old participant who died due to COPD, pneumonia and respiratory failure) and two in the placebo group (68-year-old participant who died due to metastatic bronchial cancer and 68-year-old patient with fatal myocardial infarction).",
            "startOffset": 35879,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 29667,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The frequency of antigen-specific CD4+ and CD8+ T cells expressing selected cytokine markers among CD40L, IL-2, TNF-\u03b1, IFN-\u0263, IL-13 and IL-17 and a combination of at least two of the above markers was calculated.",
            "startOffset": 29455,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 39965,
            "parents": [],
            "secId": "s0065",
            "sentence": "This is the first study to assess the safety, reactogenicity and immunogenicity of a two-dose schedule of an investigational NTHi vaccine, based on conserved NTHi surface proteins (PD and PE-PilA), in adults aged 40\u201380 years with moderate or severe COPD.",
            "startOffset": 39711,
            "title": "Discussion"
        },
        {
            "endOffset": 22131,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 22022,
                    "startOffset": 22018
                },
                "b0090": {
                    "endOffset": 22130,
                    "startOffset": 22126
                }
            },
            "secId": "s0005",
            "sentence": "PD is a highly conserved lipoprotein among encapsulated and non-encapsulated H. influenzae strains [17] that is also used as carrier in the licensed 10-valent pneumococcal conjugate vaccine (Synflorix, GSK) [18].",
            "startOffset": 21919,
            "title": "Introduction"
        },
        {
            "endOffset": 27975,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Haematological and biochemical parameters were measured before, at 7 and 30 days after each vaccination and at Days 270 and 450 (7 and 13 months post-dose 2).",
            "startOffset": 27817,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 29808,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "An exploratory analysis was performed of vaccine efficacy (VE) against AECOPD, which was a tertiary endpoint of the study.",
            "startOffset": 29686,
            "title": "Vaccine efficacy"
        },
        {
            "endOffset": 43595,
            "parents": [],
            "secId": "s0065",
            "sentence": "Definition of a protective antibody response was beyond the scope of this study since efficacy was a tertiary exploratory endpoint and thus, no specific antibody protective level was determined.",
            "startOffset": 43401,
            "title": "Discussion"
        },
        {
            "endOffset": 42955,
            "parents": [],
            "secId": "s0065",
            "sentence": "A high number of participants were excluded from the ATP cohort for immunogenicity, most commonly because of non-compliance with the blood sampling schedule, administration of a forbidden medication, or the presence of a prohibited underlying medical condition.",
            "startOffset": 42694,
            "title": "Discussion"
        },
        {
            "endOffset": 34082,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "There were three reports of grade 3 pain after the first NTHi vaccine dose and five after the second dose, all of which lasted no longer than 3 days and resolved spontaneously.",
            "startOffset": 33906,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 36579,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Facial paralysis (Bell\u2019s palsy) was reported at Day 128 after the second vaccine dose by a patient aged 54 years, which was considered by the investigator as serious, and non-serious gout was reported at Day 63 after the second dose by a 72-year-old participant.",
            "startOffset": 36317,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 20767,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 20766,
                    "startOffset": 20761
                },
                "b0015": {
                    "endOffset": 20766,
                    "startOffset": 20761
                },
                "b0020": {
                    "endOffset": 20766,
                    "startOffset": 20761
                },
                "b0025": {
                    "endOffset": 20766,
                    "startOffset": 20761
                }
            },
            "secId": "s0005",
            "sentence": "Changes in the composition of the lung microbiome are associated with COPD severity and exacerbation occurrence [2\u20135].",
            "startOffset": 20649,
            "title": "Introduction"
        },
        {
            "endOffset": 24442,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Enrolled patients had stable COPD (last exacerbation was resolved for at least 30 days), with a documented history of at least one moderate or severe AECOPD within the last 12 months.",
            "startOffset": 24259,
            "title": "Study design and patients"
        },
        {
            "endOffset": 36316,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Two pIMDs were reported in the NTHi vaccine group, neither of which was considered related to vaccination.",
            "startOffset": 36210,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 21918,
            "parents": [],
            "secId": "s0005",
            "sentence": "A multi-component investigational NTHi vaccine has been developed consisting of three conserved surface proteins in the form of two vaccine antigens: a free recombinant protein D (PD) and a recombinant fusion protein combining protein E and Pilin A (PE-PilA).",
            "startOffset": 21659,
            "title": "Introduction"
        },
        {
            "endOffset": 22364,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 22183,
                    "startOffset": 22179
                },
                "b0100": {
                    "endOffset": 22223,
                    "startOffset": 22216
                },
                "b0105": {
                    "endOffset": 22223,
                    "startOffset": 22216
                },
                "b0110": {
                    "endOffset": 22363,
                    "startOffset": 22359
                }
            },
            "secId": "s0005",
            "sentence": "PE has a role in NTHi adhesion to host tissues [19] and human complement resistance [20,21], while PilA plays a key role in biofilm formation, adherence to human epithelial cells and colonisation of the upper respiratory tract [22].",
            "startOffset": 22132,
            "title": "Introduction"
        },
        {
            "endOffset": 38232,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Exploring the T helper functionality profile of specific CD4+ T cells, no vaccine-induced IL-13 expression (associated with a type 2 T helper [Th2] profile) was detected (supplementary Fig. S2), although for all markers there was high variability in the number of specific T cells for all vaccine antigens.",
            "startOffset": 37926,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37494,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "One month after the second dose, antibody responses were significantly higher in the NTHi vaccine group than with placebo for each antigen, with lower limits of the 95% CIs of adjusted GMC ratios above 10 (Table 3).",
            "startOffset": 37279,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 42693,
            "parents": [],
            "secId": "s0065",
            "sentence": "All participants were white Europeans, limiting the generalisability of the results to other ethnic groups, and the sample size was small.",
            "startOffset": 42555,
            "title": "Discussion"
        },
        {
            "endOffset": 36886,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "A grade 4 change in haemoglobin from baseline was reported in one participant (1.4%) in the placebo group.",
            "startOffset": 36780,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 42335,
            "parents": [],
            "secId": "s0065",
            "sentence": "Exploratory analysis showed a VE point estimate of 13% (95% CI: \u221224, 39) for moderate/severe AECOPD and 10% (\u221224, 35) for any AECOPD albeit this was not statistically significant and the study was not powered for this outcome.",
            "startOffset": 42109,
            "title": "Discussion"
        },
        {
            "endOffset": 37167,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In the NTHi vaccine group, antibody GMCs against all three antigens increased after each vaccine dose, while no increases were observed in the placebo group (Fig. 4).",
            "startOffset": 37001,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 39455,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Examination of the model covariates showed a significant effect (p < 0.05) of history of AECOPD on the yearly rate of any and moderate/severe AECOPD, and of country on any AECOPD (supplementary Table S1).",
            "startOffset": 39251,
            "title": "Efficacy"
        },
        {
            "endOffset": 24758,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Exclusion criteria for the study are described in the supplementary methods.",
            "startOffset": 24682,
            "title": "Study design and patients"
        },
        {
            "endOffset": 43983,
            "parents": [],
            "secId": "s0065",
            "sentence": "Future studies will also aim to define antibody correlates of protection and will explore the relationship over time between VE and NTHi-specific antibody responses and CD4+ T cell expression.",
            "startOffset": 43791,
            "title": "Discussion"
        },
        {
            "endOffset": 24681,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Women of non-childbearing potential or on adequate contraception could be enrolled.",
            "startOffset": 24598,
            "title": "Study design and patients"
        },
        {
            "endOffset": 23320,
            "parents": [],
            "secId": "s0005",
            "sentence": "A Focus on the Patient section (Fig. 1) summarises the clinical relevance and impact of this study on the patient population.",
            "startOffset": 23195,
            "title": "Introduction"
        },
        {
            "endOffset": 40370,
            "parents": [],
            "secId": "s0065",
            "sentence": "Since the number of patients enrolled was limited, no formal statistical comparisons of reactogenicity between groups were performed.",
            "startOffset": 40237,
            "title": "Discussion"
        },
        {
            "endOffset": 23195,
            "parents": [],
            "secId": "s0005",
            "sentence": "The vaccine\u2019s humoral and cellular immunogenicity was assessed as a secondary objective and an exploratory tertiary analysis evaluated efficacy against AECOPD.",
            "startOffset": 23036,
            "title": "Introduction"
        },
        {
            "endOffset": 27531,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Solicited local (pain, redness and swelling at the injection site) and general (fatigue, fever, gastrointestinal symptoms and headache) adverse events (AEs) were recorded for 7 days after each dose on diary cards.",
            "startOffset": 27318,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 36984,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All grade 3 or 4 abnormal haemoglobin results were reported at least one month after vaccination.",
            "startOffset": 36887,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 41985,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 41984,
                    "startOffset": 41980
                }
            },
            "secId": "s0065",
            "sentence": "The NTHi-specific CMI response increased but was highly variable in terms of CD4+ T cell expression, which was similar to that observed in the phase 1 study of healthy smokers/ex-smokers in a similar age range [23].",
            "startOffset": 41770,
            "title": "Discussion"
        },
        {
            "endOffset": 41769,
            "parents": [],
            "secId": "s0065",
            "sentence": "Thereafter, antibody GMCs decreased gradually but remained above baseline levels 13 months post-dose 2.",
            "startOffset": 41666,
            "title": "Discussion"
        },
        {
            "endOffset": 36209,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "None were considered related to vaccination.",
            "startOffset": 36165,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 43790,
            "parents": [],
            "secId": "s0065",
            "sentence": "These results and those of previous studies support further clinical assessment of the vaccine in reducing the frequency of AECOPD, as well as its effect on COPD symptoms and long-term outcomes.",
            "startOffset": 43596,
            "title": "Discussion"
        },
        {
            "endOffset": 33905,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The incidence of each solicited local AE was higher in the NTHi vaccine group than in the placebo group after each dose (Fig. 3).",
            "startOffset": 33776,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 33599,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "All participants were white (European heritage).",
            "startOffset": 33551,
            "title": "Study population"
        },
        {
            "endOffset": 26450,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 26449,
                    "startOffset": 26445
                }
            },
            "secId": "s0015",
            "sentence": "The NTHi vaccine contained 10 \u00b5g PD and 10 \u00b5g PE-PilA per dose with AS01E (containing immunostimulants, 3-O-desacyl-4\u2032-monophosphoryl lipid A and saponin QS-21, 25 \u00b5g each, and liposomes), as described previously [23].",
            "startOffset": 26232,
            "title": "Study design and patients"
        },
        {
            "endOffset": 27817,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Other grade 3 AEs were defined as preventing normal activities.",
            "startOffset": 27754,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 33550,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "H. influenzae was detected in approximately one-quarter of cultured sputum samples at baseline.",
            "startOffset": 33455,
            "title": "Study population"
        },
        {
            "endOffset": 21398,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 21297,
                    "startOffset": 21293
                }
            },
            "secId": "s0005",
            "sentence": "Global Initiative for Chronic Obstructive Lung Disease (GOLD) currently recommends influenza and pneumococcal vaccines for COPD patients [12] but no vaccine is specifically indicated for the prevention of acute exacerbations of COPD (AECOPD).",
            "startOffset": 21156,
            "title": "Introduction"
        },
        {
            "endOffset": 32649,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Further details are provided in the supplement.",
            "startOffset": 32602,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41414,
            "parents": [],
            "secId": "s0065",
            "sentence": "The frequency of unsolicited AEs was similar between groups and there was only one reported vaccine-related SAE (infective exacerbation of COPD), which was in the placebo group.",
            "startOffset": 41237,
            "title": "Discussion"
        },
        {
            "endOffset": 21658,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 21657,
                    "startOffset": 21650
                },
                "b0080": {
                    "endOffset": 21657,
                    "startOffset": 21650
                }
            },
            "secId": "s0005",
            "sentence": "Consequently, the use of conserved surface-exposed proteins as vaccine antigens is being investigated as an alternative approach [15,16].",
            "startOffset": 21521,
            "title": "Introduction"
        },
        {
            "endOffset": 42554,
            "parents": [],
            "secId": "s0065",
            "sentence": "The study had limitations.",
            "startOffset": 42528,
            "title": "Discussion"
        },
        {
            "endOffset": 38408,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The study was not powered to find differences in efficacy and this was a tertiary analysis.",
            "startOffset": 38317,
            "title": "Efficacy"
        },
        {
            "endOffset": 23844,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All patients were current or former smokers (smoking history \u2265 10 pack-years).",
            "startOffset": 23766,
            "title": "Study design and patients"
        },
        {
            "endOffset": 42528,
            "parents": [],
            "secId": "s0065",
            "sentence": "When looking at covariates in the negative binomial model, only history of AECOPD (any and moderate/severe AECOPD) and country (any AECOPD only) had a significant effect on AECOPD yearly rate.",
            "startOffset": 42336,
            "title": "Discussion"
        },
        {
            "endOffset": 26986,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The protocols and associated documents were reviewed and approved by the Southampton and South West Hampshire Research Ethics Committee, UK, and Regional Research Ethics Committee, Gothenburg, Sweden.",
            "startOffset": 26786,
            "title": "Study design and patients"
        },
        {
            "endOffset": 37278,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "GMCs waned in the NTHi vaccine group after Day 90 but remained higher than baseline at subsequent time points.",
            "startOffset": 37168,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41665,
            "parents": [],
            "secId": "s0065",
            "sentence": "Antibody GMCs increased after the first vaccine dose followed by a further increase after the second dose.",
            "startOffset": 41559,
            "title": "Discussion"
        },
        {
            "endOffset": 25396,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 25395,
                    "startOffset": 25391
                }
            },
            "secId": "s0015",
            "sentence": "An exacerbation was considered mild if self-managed by the patient using inhaled therapy, moderate if it required treatment with oral corticosteroids, antibiotics or both, and severe if the patient required hospitalisation or an equivalent home care intervention [24].",
            "startOffset": 25128,
            "title": "Study design and patients"
        },
        {
            "endOffset": 27608,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Unsolicited AEs with onset during the 30 days after each dose were recorded.",
            "startOffset": 27532,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 41141,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 41140,
                    "startOffset": 41130
                },
                "b0155": {
                    "endOffset": 41140,
                    "startOffset": 41130
                },
                "b0160": {
                    "endOffset": 41140,
                    "startOffset": 41130
                }
            },
            "secId": "s0065",
            "sentence": "This may be due to enhanced activation of the innate immune response induced by the adjuvant at the injection site and increased production of cytokines and chemokines [23,31,32].",
            "startOffset": 40962,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X19310217",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Tom M.A.",
                "initial": "T.M.A.",
                "last": "Wilkinson"
            },
            {
                "email": null,
                "first": "Stuart",
                "initial": "S.",
                "last": "Schembri"
            },
            {
                "email": null,
                "first": "Christopher",
                "initial": "C.",
                "last": "Brightling"
            },
            {
                "email": null,
                "first": "Nawar D.",
                "initial": "N.D.",
                "last": "Bakerly"
            },
            {
                "email": null,
                "first": "Keir",
                "initial": "K.",
                "last": "Lewis"
            },
            {
                "email": null,
                "first": "William",
                "initial": "W.",
                "last": "MacNee"
            },
            {
                "email": null,
                "first": "Lars",
                "initial": "L.",
                "last": "Rombo"
            },
            {
                "email": null,
                "first": "Jan",
                "initial": "J.",
                "last": "Hedner"
            },
            {
                "email": null,
                "first": "Martin",
                "initial": "M.",
                "last": "Allen"
            },
            {
                "email": null,
                "first": "Paul P.",
                "initial": "P.P.",
                "last": "Walker"
            },
            {
                "email": null,
                "first": "Iris",
                "initial": "I.",
                "last": "De Ryck"
            },
            {
                "email": null,
                "first": "Annaelisa",
                "initial": "A.",
                "last": "Tasciotti"
            },
            {
                "email": null,
                "first": "Daniela",
                "initial": "D.",
                "last": "Casula"
            },
            {
                "email": null,
                "first": "Philippe",
                "initial": "P.",
                "last": "Moris"
            },
            {
                "email": "marco.x.testa@gsk.com",
                "first": "Marco",
                "initial": "M.",
                "last": "Testa"
            },
            {
                "email": null,
                "first": "Ashwani K.",
                "initial": "A.K.",
                "last": "Arora"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.07.100",
        "firstpage": "6102",
        "issn": "0264410X",
        "keywords": [
            "COPD",
            "Exacerbation",
            "Immunogenicity",
            "Non-typeable Haemophilus influenzae",
            "Safety",
            "Vaccine"
        ],
        "lastpage": "6111",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial"
    }
}